FOUNDATION FOR THE ADVANCEMENT OF CARDIOLOGY CARDIOPROGRESS
  
  KNOWLEDGE, OBSERVATION, ACTION

RUS      ENG    
        

Saturday, 22 September 2018

HomeAboutInternational Forum of Cardiology and Internal MedicineRussian Cardio AgendaWorld Cardio AgendaEducational projectsGuidelineslinical trialsJournalsNewsArchive

News
  • Antihypertensive Therapy Reduces Alzheimer"s, Dementia Risk ...
  • Studies Find No Easy Predictors of Stroke Prevention in TAVR ...
  • Statins in Peripheral Artery Disease: What Are We Waiting For? ...
  • Beta-Blockers May Raise Mortality in People With Diabetes ...
  • Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Func ...
     

    Partnership
    The Department of Health in Moscow
    The State Committee on Health
    Silicea-Poligraf, publishing house

    Follow us:
    @moscowcardio               Facebook

     <<  return

     

    Late-Breaking Clinical Trials

    Late-Breaking Clinical Trials sessions are innovative, provide the latest breakthroughs in clinical science and potentially will have a significant impact on clinical practice. Clinical Science Report sessions will highlight trial updates, registries and important clinical science.



    Failure is Not an Option: New Drugs and Systems of Care

    November 8, 2015, 3:45 pm

    • A Randomized Trial of Liraglutide for High-Risk Heart Failure Patients With Reduced Ejection Fraction
    • Nitrate"s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction (NEAT-HFpEF
    • Oral sGC Stimulator Vericiguat in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction - The SOluble guanylate Cyclase stimulatoR in heArT failurE patientS With REDUCED EF (SOCRATES-REDUCED) Study
    • Remote Patient Management After Discharge of Hospitalized Heart Failure Patients: The Better Effectiveness After Transition - Heart Failure Study


    Decreasing the Global Burden of Disease: Breakthroughs in Prevention

    November 9, 2015, 10:45 am

    • The Efficacy and Safety of Varenicline, a Selective Alpha4beta2 Nicotinic Receptor Partial Agonist, for Smoking Cessation in Patients Hospitalized With Acute Coronary Syndrome: A Randomized Controlled Trial
    • Impact of a Comprehensive Lifestyle Peer-group-based Intervention on Cardiovascular Risk Factors: A Randomized Controlled Trial
    • Clinical Trial of a Mobile Health Intervention for Simultaneous versus Sequential Diet and Activity Change
    • The Effect of Disclosing Genomic Risk of Coronary Heart Disease on Low-density Lipoprotein Cholesterol Levels: The Myocardial Infarction Genes (MI-GENES) Study
    • Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk


    Two-Year Clinical Update: CT Surgery Network Severe MR Trial
    November 9, 2015, 1:30 pm

    • Two-Year Outcomes following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation


    SPRINT Trial Results: Latest News in Hypertension Management
    November 9, 2015, 2:00 pm

    • Systolic Blood Pressure Intervention Trial (SPRINT)

    ACS and PCI: The Continuum of Care

    November 10, 2015, 10:45 am

    • Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT-4)
    • Clinical Outcomes of Intravascular Ultrasound Guided Everolimus-Eluting Stents Implantation in Long Coronary Lesions
    • Long-Term Tolerability of Ticagrelor in the PEGASUS-TIMI 54 Trial
    • Individualizing Treatment Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: An Analysis of the DAPT Study
    • Angina and Quality of Life Following PCI With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial


    Novel Therapies for Common Problems

    November 11, 2015, 10:45 am

    • One Year Follow-up Results From AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation With Algisyl-LVR in the Treatment of Heart Failure
    • The-First-in-Man Randomized Trial of a β3-adrenoceptor Agonist in Chronic Heart Failure - the BEAT-HF Trial
    • Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial
    • ANNEXA™-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors
    • Prevention of Acute Kidney Injury by Nitric Oxide During and After Prolonged Cardiopulmonary Bypass. A Double Blind Randomized Controlled Trial
    • A Randomized, Placebo Controlled Trial of Late Na Channel Inhibition (ranolazine) in Coronary Microvascular Dysfunction (CMD): Impact on Angina and Myocardial Ischemia
    • ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins

     


    Clinical Science Special Report Sessions


    Novel Findings from Next Generation Registries

    November 9, 2015, 9:00 am

    • Increased Incidence of Infective Endocarditis After the 2009 European Society of Cardiology Guideline Update: A Nation-wide Study in the Netherlands
    • Examining Prevailing Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy: Findings From The Sarcomeric Human Cardiomyopathy Registry (SHaRe)
    • Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention – Findings From the NCDR-CathPCI Registry
    • Clopidogrel on Top of Aspirin for the Prevention of New-onset Migraine Headache Attacks Following Transcatheter Closure of Atrial Septal Defects: A Prospective, Randomized, Double Blind Trial (CANOA)


    Cutting Edge Technologies in EP

    November 9, 2015, 3:45 pm

    • Cardiac Resynchronization Therapy is Detrimental in Patients With QRS Duration Greater Than 180ms and Right Bundle Branch Block Morphology: Analysis From the Medicare ICD Registry
    • Miniaturized Transcatheter Delivered Cardiac Pacing: Primary Results of a Worldwide Clinical Trial
    • A Randomized Controlled Trial of a Video Decision Support Tool to Depict Goals of Care and Resuscitation Options for Patients With Advanced Heart Failure
    • Peri-procedural Safety of Left Atrial Appendage Occlusion With the WATCHMAN Device. Preliminary Data From the EWOLUTION Registry


    Managing Risk Factors for CAD—Clinical Trial Updates

    November 10, 2015, 3:45 pm

    • Cholesterol Treatment Targets and Clinical Outcomes: A JUPITER Trial Update
    • Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular and Non-Cardiovascular Mortality: A Population-Based Study of More than 630,000 Individuals Without Prior Cardiovascular Conditions in Ontario, Canada
    • Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: the Action to Control Cardiovascular Risk in Diabetes Follow-On Blood Pressure Study

    Revascularization in Patients With Diabetes and Multivessel Coronary Artery Disease: A Population Based Evaluation of Outcomes





    Feedback

    Contact us: by  

    Editor-in-chief:  

    @Mail.ru
    Main | About | International Forum of Cardiology and Internal Medicine | Russian Cardio Agenda | World Cardio Agenda | Educational projects | Guidelines | linical trials | Journals | News | Archive
    2012-2018. Foundation for Promotion of Cardiology